Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, announced terms for its IPO on Monday.
The Hamilton, Bermuda-based company plans to raise $176 million by offering 13 million shares at a price range of $12 to $15. At the midpoint of the proposed range, Myovant Sciences would command a fully diluted market value of $802 million.
Myovant Sciences was founded in 2016. It plans to list on the NYSE under the symbol MYOV. Citi, Cowen & Company, Evercore ISI and Barclays are the joint bookrunners on the deal. It is expected to price during the week of October 24, 2016.
